- Home
- TSHA vs QUAD Comparison
TSHA vs QUAD Comparison
Compare TSHA & QUAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSHA
- QUAD
- Stock Information
- Founded
- TSHA 2019
- QUAD 1971
- Country
- TSHA United States
- QUAD United States
- Employees
- TSHA N/A
- QUAD N/A
- Industry
- TSHA Biotechnology: Pharmaceutical Preparations
- QUAD Publishing
- Sector
- TSHA Health Care
- QUAD Consumer Discretionary
- Exchange
- TSHA Nasdaq
- QUAD Nasdaq
- Market Cap
- TSHA 356.7M
- QUAD 287.7M
- IPO Year
- TSHA 2020
- QUAD 2010
- Fundamental
- Price
- TSHA $1.26
- QUAD $5.53
- Analyst Decision
- TSHA Strong Buy
- QUAD Strong Buy
- Analyst Count
- TSHA 8
- QUAD 2
- Target Price
- TSHA $6.63
- QUAD $10.15
- AVG Volume (30 Days)
- TSHA 2.4M
- QUAD 223.6K
- Earning Date
- TSHA 05-13-2025
- QUAD 04-29-2025
- Dividend Yield
- TSHA N/A
- QUAD 4.09%
- EPS Growth
- TSHA N/A
- QUAD N/A
- EPS
- TSHA N/A
- QUAD N/A
- Revenue
- TSHA $8,333,000.00
- QUAD $2,672,200,000.00
- Revenue This Year
- TSHA N/A
- QUAD N/A
- Revenue Next Year
- TSHA N/A
- QUAD N/A
- P/E Ratio
- TSHA N/A
- QUAD N/A
- Revenue Growth
- TSHA N/A
- QUAD N/A
- 52 Week Low
- TSHA $1.17
- QUAD $4.06
- 52 Week High
- TSHA $4.32
- QUAD $9.13
- Technical
- Relative Strength Index (RSI)
- TSHA 32.22
- QUAD 42.51
- Support Level
- TSHA $1.17
- QUAD $5.29
- Resistance Level
- TSHA $1.87
- QUAD $5.58
- Average True Range (ATR)
- TSHA 0.17
- QUAD 0.16
- MACD
- TSHA -0.04
- QUAD 0.04
- Stochastic Oscillator
- TSHA 12.18
- QUAD 52.17
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
About QUAD Quad Graphics Inc
Quad/Graphics Inc provides print and marketing services to help customers market their products, services, and contents. The company operates in the commercial segment of the printing industry. It operates through three divisions. The United States print and related services segment consists of the company's American operations. Besides the complete set of print and marketing solutions, this segment also manufactures ink. The international segment includes the company's printing business in Europe and Latin America. The corporate segment is engaged in the general and administrative activities as well as associated costs. The company almost generates all its revenue from the American domestic market.